SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending after announcing a deal with OpenAI, which includes stock warrants and designates AMD as a core compute partner. The community is discussing the potential impact of this partnership on AMD's market share and revenue, with some speculating on future price targets. Broader discussions involve the AI infrastructure race and comparisons to Nvidia's position in the market.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending amid speculation of a potential partnership with Tesla, fueled by a recent video showcasing Archer's eVTOL aircraft alongside Tesla's Optimus robot. The community is actively discussing the possibility of Tesla integrating Archer's technology for autonomous air taxis and battery solutions. This buzz comes as Archer progresses towards regulatory approvals and expands into defense applications.

Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

Spruce Biosciences Inc

SPRB is trending due to a significant surge following the FDA's Breakthrough Therapy Designation for its treatment of Sanfilippo syndrome type B. The community is discussing the potential for a short squeeze, fueled by the stock's low float and recent reverse split, while comparing it to other high-flying stocks and anticipating further upward momentum.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin ($APP) is trending due to reports of an SEC probe into its data collection practices, leading to a sharp decline in its stock price. The community is debating whether this is a buying opportunity or a sign of deeper issues, with some pointing to past short-seller reports and inflated valuations. Despite the recent surge driven by AI optimism and S&P 500 inclusion, the stock's future is uncertain as investors assess the potential impact of the investigation.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is trending due to a significant after-hours drop following its earnings report, where the company reported a year-over-year revenue decrease and did not issue formal guidance. Community members are actively discussing the company's cash burn, inventory levels, and the lack of specific guidance, with some anticipating a potential offering. Despite the concerns, some bulls remain optimistic about the company's wafer-level testing technology and potential in the AI market.

BlackRock Institutional Trust Company N.A. - iShares Gold Trust

iShares Gold Trust

IAU is trending as gold prices reach record highs, fueled by safe-haven demand amidst US government shutdown concerns and a weaker dollar. The community is actively discussing potential further upside, with some analysts predicting prices could climb significantly higher. Investors are monitoring factors like potential Fed rate cuts and geopolitical tensions as key drivers for continued growth.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as investors discuss the potential of deep-sea mining for critical minerals and the company's strong fundamentals. Community members are weighing the potential for government investment and comparing TMC to other companies in the sector. Some are also focused on technical analysis, noting a potential cup and handle formation.

This is a legacy token commemorating the pseudonym Satoshi Nakamoto.

Satoshi Nakamoto

$SATOSHI is trending as the community rallies around the idea of tokenizing the legacy of Satoshi Nakamoto, viewing it as the 'Bitcoin of Memes' with unlimited potential. Community members express strong conviction, emphasizing the movement's timeless nature and the significance of owning a piece of crypto history. The conversation highlights the idea that 'We are all Satoshi', suggesting a broad appeal and a shared identity within the crypto space.

Rio Tinto Plc engages in the exploration, mining, and processing of mineral resources. It operates through the following business segments: Iron Ore, Aluminium, Copper, and Minerals. The Iron Ore segment supplies iron ore mining and salt and gypsum production. The Aluminium segment produces bauxite, alumina and primary aluminum. The Copper segment offers gold, silver, molybdenum and other by-products. The Minerals includes businesses with products such as uranium, borates, salt and titanium dioxide feedstock together with coal operations. The Other Operations segment covers the curtailed Gove alumina refinery and Rio Tinto Marine operations. The company was founded in 1873 and is headquartered in London, the United Kingdom.

Rio Tinto plc - ADR

Rio Tinto plc

Rio Tinto is trending due to potential growth in the lithium sector following reports of a partnership to develop lithium extraction technology in Chile and speculation around mergers and acquisitions. Community discussions are centered on the company's long-term value, dividend payouts, and copper projects. Some investors express frustration with the stock's price action while others view it as a buying opportunity, citing strong financials and potential benefits from a Trump presidency.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending as investors speculate about potential deals and partnerships, possibly with major players like AMD and OpenAI, driving the stock to all-time highs. The community is actively discussing the company's shift towards AI infrastructure and data centers, as well as its Bitcoin mining operations. Bullish sentiment is fueled by comparisons to high-growth tech companies and the anticipation of significant revenue increases.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Retail chatter around Cogent Biosciences surged on Tuesday as multiple firms raised their price targets following strong results from the Phase 3 Summit trial of bezuclastinib in non-advanced systemic mastocytosis (NonAdvSM).The Summit Part 2 trial met its primary endpoint with a statistically significant placebo-adjusted improvement of 8.91 points in total symptom score (TSS) at 24 weeks.&nbsp;Patients treated with bezuclastinib saw a mean TSS reduction of 24.3 points, compared to 15.4 points for placebo.&nbsp;The drug also met all key secondary endpoints, including reductions in serum tryptase, with 87.4% of treated patients achieving at least a 50% drop versus none in the control group.&nbsp;Most adverse events were low-grade. Discontinuations due to side effects occurred in 5.9% of patients, all of whom recovered.H.C. Wainwright raised its price target to $22 from $12 and maintained a 'Buy' rating, raising its approval probability estimate to 95% from 60%, calling bezuclastinib a potential new standard of care.&nbsp;Jefferies lifted its target to $28 from $23 with a 'Buy' rating, citing a “home run” outcome and a $1 billion market opportunity in ISM alone.Leerink increased its target to $18 from $16 and reiterated an 'Outperform' rating, noting the safety profile exceeded expectations and pointing to strong positioning ahead of the Peak and Apex trial readouts due later in 2025.&nbsp;Baird took a more conservative view, raising its target to $9 from $7 while maintaining a 'Neutral' rating, stating that the results were better than the worst-case scenario but fell short of the best.Cogent remains on track to submit a new drug application (NDA) for bezuclastinib by year-end 2025 and will present detailed Summit findings at a medical conference later this year.Separately, Cogent announced a proposed public offering of $150 million in common stock.&nbsp;The company said proceeds will support continued development, regulatory and commercial preparation for bezuclastinib and other pipeline candidates, as well as general corporate purposes.&nbsp;On Stocktwits, retail sentiment for Cogent was ‘extremely bullish’ amid ‘extremely high’ message volume.<a href="https://stocktwits.com/symbol/COGT">Cogent’s stock</a> has risen 25.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Multiple firms raised their price targets on Cogent Biosciences (COGT) following strong results from the Phase 3 Summit trial of bezuclastinib/Photo credit: Getty Images

Cogent Biosciences Scores Analyst Praise As Mastocytosis Drug Hits Trial Goals; Retail Buzz Surges

Bezuclastinib met all primary and secondary endpoints in a Phase 3 trial for non-advanced systemic mastocytosis, with analysts highlighting strong efficacy, safety, and commercial potential.

Equity

COGT Stock Soars on Phase III Systemic Mastocytosis Study Success

Cogent Biosciences stock jumps 23.4% after bezuclastinib hits primary and all key secondary endpoints in a phase III systemic mastocytosis study.

Wall Street Analysts Believe Cogent Biosciences (COGT) Could Rally 224.37%: Here's is How to Trade

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cogent Biosciences, Inc. (NASDAQ: COGT)

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cogent Biosciences, Inc. (NASDAQ: COGT) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder...

Commit To Buy Cogent Biosciences At $5, Earn 21.4% Annualized Using Options

Investors eyeing a purchase of Cogent Biosciences Inc (COGT) stock, but tentative about paying the going market price of 6.62/share, might benefit from considering selling puts among the...

Cogent Biosciences (COGT, $6.9) Aroon Indicator entered a Downtrend on April 01, 2024.

For the last three days, A.I.dvisor has detected that COGT's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Cogent Biosciences (COGT, $6.9) entered Downtrend as Momentum indicator drops below 0 level on Apr 01, 2024

This indicator may be signaling that COGT's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Cogent Biosciences files to sell 31.2M shares of common stock for holders

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Cogent Biosciences (COGT, $6.72) entered Uptrend as Momentum indicator ascends above 0 level on Mar 28, 2024

This indicator may be signaling COGT's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...

Cogent Biosciences (COGT, $6.72) Stochastic Oscillator left the oversold zone on March 28, 2024

This is a signal that COGT's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...

Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.

Cogent Biosciences Inc

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

COGT
Cogent Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest COGT News

COGT Cogent Biosciences Inc